SynAct Pharma
SynAct Pharma AB (publ) ("SynAct") brings forward the publication of the annual report.
SynAct Pharma AB (publ) ("SynAct") has decided to bring forward the publication of the annual report for the financial year 2023 to March 26, 2024.
The previous date for publication of the Annual Report for the financial year 2023 was April 10, 2024, but is now brought forward to March 26, 2024.
For further information, please contact:
CFO, Björn Westberg
Telefon: +46 703 33 91 23
E-post: investor.relations@synactpharma.com
About SynAct Pharma AB
SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical-stage biotechnology company focused on resolving inflammation through selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation-resolving activity to help patients achieve immune balance and overcome their inflammation. For more information, please contact: www.synactpharma.com.
| Datum | 2024-03-25, kl 17:45 |
| Källa | MFN |
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!